Eloxx reports third quarter 2026 results and clinical progress
Net loss widens to $5.5 million on higher R&D; cash of $56.3 million funds operations into 2028. It also names T.R. Srinivas chief medical officer.
See the latest news and media coverage for Eloxx. We track all announcements, press releases, and industry mentions in real time, all in one place.
Clinical-stage biotech developing investigational treatments for rare kidney diseases
eloxxpharma.comLast updated
In short: Eloxx published Phase 2a Alport data, advanced its ADPKD trial and began dosing its Phase 2b Alport study.
Net loss widens to $5.5 million on higher R&D; cash of $56.3 million funds operations into 2028. It also names T.R. Srinivas chief medical officer.
The clearance lets Eloxx open U.S. sites for EXPRESS, a Phase 2 trial randomizing about 60 patients for 52 weeks with htTKV growth as the primary endpoint.
It completed a $66.0 million public offering, uplisted to Nasdaq, and plans a Phase 2b trial of exaluren in Alport syndrome in Q3 2026. Cash stood at $62.0 million.
It offers 2,975,000 shares at $11.00 and pre-funded warrants for 3,025,000 shares at $10.99, with trading on the Nasdaq Capital Market expected June 9.
Safety. Exaluren was well tolerated, with no serious adverse events, study discontinuations, nephrotoxicity or ototoxicity, including in adolescents with pre-existing kidney and hearing impairment. Most...
Eloxx Pharmaceuticals, Inc. reported earnings results for the third quarter and nine months ended September 30, 2026. For the third quarter, the company reported net...
Eloxx Pharmaceuticals, Inc. (Nasdaq: ELOX) is a clinical-stage biopharmaceutical company developing novel, small-molecule product candidates designed to modulate the ribosome and promote readthrough of premature...
ARLINGTON, Mass., June 8, 2026 /PRNewswire/ -- Eloxx Pharmaceuticals, Inc. (Nasdaq: ELOX) ("Eloxx" and the "Company"), a clinical-stage biopharmaceutical company developing novel, small molecule product...
Track Eloxx and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Discover what's making headlines across other trending companies.